Constellation Energy stock edges lower as PJM power prices spike in deep freeze — what to watch next for CEG
28 January 2026
1 min read

Constellation Energy stock edges lower as PJM power prices spike in deep freeze — what to watch next for CEG

New York, Jan 28, 2026, 13:55 EST — Regular session

Shares of Constellation Energy Corp slipped 0.2% to $288.12 in Wednesday afternoon trading, moving within a range of $286.60 to $296.50. Roughly 1.6 million shares changed hands.

A power-market squeeze is gripping the U.S. Mid-Atlantic as temperatures drop. PJM Interconnection, which oversees electricity delivery for 67 million people across 13 states plus Washington, D.C., reported that transmission congestion pushed spot prices above $1,000 per megawatt hour (MWh) in parts of its region this week. The tight grid conditions have also increased the chances of controlled outages. 1

PJM is grappling with outages linked to limited natural gas supply and the cold snap. On Sunday, it reported almost 21 gigawatts of generation outages—about 16% of demand—and issued a pre-emergency call for some customers to reduce electricity use. “The Eastern seaboard relies on a pipeline network that is historically constricted” during extended cold spells, said Pieter Mul, an associate partner at PA Consulting. 2

Constellation gained 1.22% on Tuesday, bouncing back from Monday’s 1.31% drop, according to MarketWatch data. Despite the rally, the stock remains roughly 30% under its 52-week peak hit in October. 3

Peers showed varied moves today. Vistra edged down 0.1%, NRG Energy dropped close to 0.8%, but Talen Energy climbed about 1.1%.

Constellation’s nuclear fleet continues to draw investor attention amid growing demand for reliable power in the U.S. In December, the company announced that regulators granted 20-year license renewals for its Clinton and Dresden nuclear plants. Bryan Hanson, the chief generation officer, said the extensions will keep the plants running “another two decades.” 4

The company wrapped up its acquisition of Calpine earlier this month and is now integrating the firm. Constellation says this deal positions it as the largest electricity producer in the U.S. 5

High spot prices don’t guarantee bigger profits. Plenty of generators lock in prices through hedging, and winter strain can backfire if outages or operational glitches hit plants that might have gained from the price spike.

Investors are also watching for Constellation’s upcoming earnings report, which Nasdaq’s calendar currently projects for around Feb. 17. 6

Stock Market Today

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy
Previous Story

Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy

Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks
Next Story

Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Go toTop